SCHEMBL5230185

SCHEMBL5230185

CN1CCCCC1c1nnc2n1C(Cc1ccc(Cl)c(Cl)c1)C(=O)N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)CC2

nearest known ligand 0.36

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 2/20 0.36
▸ MDM2 Q00987 1/20 0.34
▸ TACR1 P25103 3/20 0.33
▸ TACR2 P21452 2/20 0.33
▸ SIGMAR1 Q99720 1/20 0.32
▸ PREP P48147 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CCR1 P32246 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234154 0.83 POLB (0.39) SRCTACR1TACR2PREPALDH1A1
SCHEMBL5230925 0.80 CNR2 (0.33) SRCTACR1TACR2ALDH1A1
SCHEMBL5234244 0.78 SIGMAR1 (0.40) TACR1TACR2SIGMAR1ALDH1A1
SCHEMBL5232486 0.76 WDR5 (0.35) SRCTACR1ALDH1A1
SCHEMBL5235425 0.75 TACR1 (0.37) SRCTACR1TACR2ALDH1A1
SCHEMBL5235420 0.75 TACR1 (0.37) SRCTACR1TACR2ALDH1A1
SCHEMBL5234199 0.75 WDR5 (0.37) TACR1ALDH1A1
SCHEMBL5234192 0.75 WDR5 (0.37) TACR1ALDH1A1
SCHEMBL5229738 0.73 CNR2 (0.38) SRCTACR1TACR2SIGMAR1ALDH1A1
SCHEMBL5235531 0.70 MAPT (0.42) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP claimed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP claimed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 SRC 2638/4885MDM2 4509/4885TACR1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback